Earnings Call Summary | Dare Bioscience(DARE.US) Q1 2024 Earnings Conference
Earnings Call Summary | Dare Bioscience(DARE.US) Q1 2024 Earnings Conference
The following is a summary of the Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript:
以下是達瑞生物科學公司（DARE）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Dare reported Q1 2024 general and administrative expenses of approximately $2.7 million.
R&D expenses were approximately $3.3 million—a 34% decrease compared to Q1 2023.
The Company's loss for the quarter was approximately $6.8 million.
Dare ended the quarter with $3.6 million in cash and equivalents.
Dare secured a non-dilutive strategic royalty financing of $22 million and received total grant funding of approximately $1.8 million.
戴爾報告稱，2024年第一季度的一般和管理費用約爲270萬美元。
研發費用約爲330萬美元，與2023年第一季度相比下降了34％。
該公司本季度的虧損約爲680萬美元。
Dare在本季度末獲得了360萬美元的現金及等價物。
Dare獲得了2200萬美元的非稀釋性戰略特許權使用費融資，並獲得了總額約180萬美元的撥款。
Business Progress:
業務進展：
Dare's product, XACIATO, is now available via prescription nationwide for treating bacterial vaginosis.
The Company is preparing for Phase 3 clinical trials of Sildenafil Cream 3.6% and Ovaprene.
They completed an end-of-Phase 2 meeting with the FDA regarding Sildenafil Cream.
Technological proof-of-concept for DARE-LARC1, Dare's pre-clinical candidate, was announced.
The company continues collaborations with major corporations including Organon for XACIATO and Bayer for Ovaprene.
Dare is planning to initiate a Sildenafil Phase 3 trial in early 2024, hopeful of it being the first Phase 3 study for female sexual arousal disorder.
The company is also progressing with DARE-LARC, a technology similar to 'Nexplanon', and is developing therapies for menopausal vasomotor symptoms and sexual pain.
Dare aims to position women's health at the forefront of innovation.
Dare的產品XACIATO現已在全國範圍內通過處方上市，用於治療細菌性****病。
該公司正在爲3.6％的西地那非乳膏和Ovaprene的3期臨床試驗做準備。
他們完成了與美國食品藥品管理局關於西地那非霜的第二階段末會議。
Dare的臨床前候選藥物 DARE-LARC1 的技術概念驗證已經公佈。
該公司繼續與包括XACIATO的Organon和Ovaprene的拜耳在內的大公司合作。
Dare計劃在2024年初啓動西地那非3期試驗，希望這是第一項針對女性性喚起障礙的3期研究。
該公司還在開發類似於 “Nexplanon” 的DARE-LARC技術方面取得進展，並且正在開發針對更年期血管舒縮症狀和性疼痛的療法。
Dare旨在將女性健康置於創新的最前沿。
More details: Dare Bioscience IR
更多詳情： Dare 生物科學 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。